^
No biomarker
|
NHL
|
No biomarker
|
NHL
|
C-CAR039 Sensitive: B - Late Trials
PRNewswire - 2 weeks
|
C-CAR039 Sensitive: B - Late Trials
PRNewswire - 2 weeks
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - Today
|
lisocabtagene maraleucel Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - Today
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
ALK positive
|
NHL
|
ALK positive
|
NHL
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Lymphoma
|
No biomarker
|
Lymphoma
|
axicabtagene ciloleucel Resistant: A1 - Approval
|
axicabtagene ciloleucel Resistant: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Burkitt Lymphoma
|
No biomarker
|
Burkitt Lymphoma
|
cyclophosphamide Sensitive: A1 - Approval
|
cyclophosphamide Sensitive: A1 - Approval
|
No biomarker
|
Burkitt Lymphoma
|
No biomarker
|
Burkitt Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
ICP-022 Sensitive: A1 - Approval
|
ICP-022 Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
ICP-022 Sensitive: A1 - Approval
|
ICP-022 Sensitive: A1 - Approval
|
TNFRSF8 positive
|
HL
|
TNFRSF8 positive
|
HL
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
lenalidomide Sensitive: A1 - Approval
|
lenalidomide Sensitive: A1 - Approval
|
CD20 expression
|
NHL
|
CD20 expression
|
NHL
|
rituximab-arrx Sensitive: A1 - Approval
|
rituximab-arrx Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
rituximab + lenalidomide Sensitive: A1 - Approval
|
rituximab + lenalidomide Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
Rixathon (rituximab biosimilar) Sensitive: A1 - Approval
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
obinutuzumab Sensitive: A1 - Approval
|
obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
temsirolimus Sensitive: A1 - Approval
|
temsirolimus Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab + polatuzumab vedotin Sensitive: A1 - Approval
|
rituximab + polatuzumab vedotin Sensitive: A1 - Approval
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
pixantrone Sensitive: A1 - Approval
|
pixantrone Sensitive: A1 - Approval
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
T Cell Non-Hodgkin Lymphoma
|
No biomarker
|
T Cell Non-Hodgkin Lymphoma
|
nelarabine Sensitive: A1 - Approval
|
nelarabine Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
TNFRSF8 positive
|
Cutaneous T-cell Lymphoma
|
TNFRSF8 positive
|
Cutaneous T-cell Lymphoma
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
CD20 positive
|
Follicular Lymphoma
|
CD20 positive
|
Follicular Lymphoma
|
rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval
|
rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
ibritumomab tiuxetan Sensitive: A1 - Approval
|
ibritumomab tiuxetan Sensitive: A1 - Approval
|
No biomarker
|
Cutaneous T-cell Lymphoma
|
No biomarker
|
Cutaneous T-cell Lymphoma
|
bexarotene oral Sensitive: A1 - Approval
|
bexarotene oral Sensitive: A1 - Approval
|
TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
TNFRSF8 expression
|
Peripheral T-cell Lymphoma
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
idelalisib Sensitive: A1 - Approval
|
idelalisib Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
CD20 positive
|
NHL
|
CD20 positive
|
NHL
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
lenalidomide + tafasitamab Sensitive: A1 - Approval
|
lenalidomide + tafasitamab Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
duvelisib Sensitive: A1 - Approval
|
duvelisib Sensitive: A1 - Approval
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
belinostat Sensitive: A1 - Approval
|
belinostat Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
loncastuximab tesirine Sensitive: A1 - Approval
|
loncastuximab tesirine Sensitive: A1 - Approval
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
pralatrexate Sensitive: A1 - Approval
|
pralatrexate Sensitive: A1 - Approval
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
selinexor Sensitive: A1 - Approval
|
selinexor Sensitive: A1 - Approval
|
EZH2 wild-type
|
Follicular Lymphoma
|
EZH2 wild-type
|
Follicular Lymphoma
|
tazemetostat Sensitive: A1 - Approval
|
tazemetostat Sensitive: A1 - Approval
|
EZH2 mutation
|
Follicular Lymphoma
|
EZH2 mutation
|
Follicular Lymphoma
|
tazemetostat Sensitive: A1 - Approval
|
tazemetostat Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
copanlisib Sensitive: A1 - Approval
|
copanlisib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
venetoclax Sensitive: A1 - Approval
|
venetoclax Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
duvelisib Sensitive: A1 - Approval
|
duvelisib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
umbralisib Sensitive: A1 - Approval
|
umbralisib Sensitive: A1 - Approval
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
umbralisib Sensitive: A1 - Approval
|
umbralisib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
rituximab + bortezomib Sensitive: A1 - Approval
|
rituximab + bortezomib Sensitive: A1 - Approval
|
No biomarker
|
Cutaneous T-cell Lymphoma
|
No biomarker
|
Cutaneous T-cell Lymphoma
|
vorinostat Sensitive: A1 - Approval
|
vorinostat Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
acalabrutinib Sensitive: A1 - Approval
|
acalabrutinib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
bortezomib Sensitive: A1 - Approval
|
bortezomib Sensitive: A1 - Approval
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
IL2RA expression
|
Cutaneous T-cell Lymphoma
|
IL2RA expression
|
Cutaneous T-cell Lymphoma
|
denileukin diftitox Sensitive: A1 - Approval
|
denileukin diftitox Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
lisocabtagene maraleucel Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - Today
|
lisocabtagene maraleucel Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - Today
|
CD20 positive
|
Follicular Lymphoma
|
CD20 positive
|
Follicular Lymphoma
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Peripheral T-cell Lymphoma
|
No biomarker
|
Peripheral T-cell Lymphoma
|
denileukin diftitox Sensitive: A1 - Approval
|
denileukin diftitox Sensitive: A1 - Approval
|
No biomarker
|
Cutaneous T-cell Lymphoma
|
No biomarker
|
Cutaneous T-cell Lymphoma
|
denileukin diftitox Sensitive: A1 - Approval
|
denileukin diftitox Sensitive: A1 - Approval
|
CD20 positive
|
NHL
|
CD20 positive
|
NHL
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
rituximab/hyaluronidase Sensitive: A1 - Approval
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
CD20 positive
|
Diffuse Large B Cell Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
avapritinib Sensitive: A1 - Approval
|
avapritinib Sensitive: A1 - Approval
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
recombinant Erwinia asparaginase Sensitive: A1 - Approval
|
recombinant Erwinia asparaginase Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
AK105 Sensitive: A1 - Approval
|
AK105 Sensitive: A1 - Approval
|
No biomarker
|
HL
|
No biomarker
|
HL
|
AB122 Sensitive: A1 - Approval
|
AB122 Sensitive: A1 - Approval
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
bendamustine Sensitive: A1 - Approval
|
bendamustine Sensitive: A1 - Approval
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
bendamustine RTD Sensitive: A1 - Approval
|
bendamustine RTD Sensitive: A1 - Approval
|
CD20 positive
|
NHL
|
CD20 positive
|
NHL
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
Ruxience (rituximab biosimilar) Sensitive: A1 - Approval
|
CD20 positive
|
Burkitt Lymphoma
|
CD20 positive
|
Burkitt Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
R-CVP Sensitive: A2 - Guideline
|
R-CVP Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
R-CHOP Sensitive: A2 - Guideline
|
R-CHOP Sensitive: A2 - Guideline
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
rituximab + lenalidomide Sensitive: A2 - Guideline
|
